ARC-EX: the first non-invasive stimulation that restores hand function after spinal cord injury

Published · Researched 2026-09-22

What happened (dated facts)

On December 19, 2024, the U.S. FDA granted de novo classification and market authorization to ONWARD Medical's ARC-EX System — the world's first non-invasive spinal cord stimulation system for people with chronic spinal cord injury. The system delivers programmed electrical stimulation through the skin to the spinal cord via electrodes on the back of the neck, with no surgery required. The authorization followed the multisite Up-LIFT pivotal trial, which showed the technology improves hand strength and sensation in people whose injuries happened years — even decades — earlier. First commercial sales followed in January 2025 (UW Medicine and Next Steps Chicago), and the system was named a 2024 TIME Magazine Best Invention and designated an FDA Breakthrough Device.

Why it is genuinely positive

People with chronic spinal cord injury have long been told nothing more can be done — especially for hand function lost years ago. A non-invasive device, proven in a pivotal trial to restore grip strength and sensation and now FDA-authorized and selling to rehab centers, turns "nothing can be done" into a treatment pathway.

Social pulse

Strong neurotech-press circulation around the December 2024 FDA authorization (IEEE Pulse, ONWARD Medical). A targeted Threads search was run; results pending at time of writing. The social layer here is health-tech media rather than viral patient posts.

Verified quotes

None captured. (Company quote available in press release: Dave Marver, CEO: "For the first time, there is an approved therapy shown to improve hand strength and sensation after chronic SCI" — company statement, not independently verified verbatim.)

Verification

• Tier: 2
• Primary source: ONWARD Medical press release via GlobeNewswire (https://www.globenewswire.com/news-release/2024/12/19/3000089/0/en/ONWARD-Medical-Receives-FDA-De-Novo-Classification-and-US-Market-Authorization-for-World-s-First-Non-Invasive-Spinal-Cord-Stimulation-System-for-People-with-Chronic-Spinal-Cord-Inj.html), December 19, 2024; corroborated by IEEE Pulse (https://www.embs.org/pulse/articles/fda-cleared-noninvasive-spine-stimulation-system-could-transform-spinal-cord-injury-treatment/), August 2025. Proves: de novo authorization date; first non-invasive SCI stimulation; Up-LIFT trial hand strength/sensation improvement; first commercial sales January 2025.
• Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
• Positivity check: authorized therapy with pivotal-trial functional improvement — genuine; substitutes the adaptive-DBS slot whose outcome magnitudes could not be verified.

Key facts

UNVERIFIED points

• Social-layer posts about ARC-EX were not yet observed; tier cannot be finalized until they are.
• Precise Up-LIFT trial effect magnitudes (e.g., percentage improving, grip-strength deltas) were not captured verbatim this session; the dossier states only the verified directional outcome.
• This dossier REPLACES 32-adaptive-dbs-parkinsons.md (substitution logged in category report and manifest).

Sources

• Primary source: ONWARD Medical press release via GlobeNewswire ( — retrieval date not recorded
• Primary source: ONWARD Medical press release via GlobeNewswire (https://www.globenewswire.com/news-release/2024/12/19/3000089/0/en/ONWARD… — retrieval date not recorded